Asian Pacific Journal of Cancer Prevention

  • 제16권6호
  • /
  • Pages.2441-2445
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Malignancy Risk Scoring of Hydatidiform Moles

  • Pradjatmo, Heru (Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Dasuki, Djaswadi (Department of Obstetric and Gynecology, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Dwianingsih, Ery Kus (Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada) ;
  • Triningsih, Ediati (Department of Anatomical Pathology, Faculty of Medicine, Universitas Gadjah Mada)
  • 발행 : 2015.04.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Several risk factors leading to malignant transformation of hydatidiform moles have been described previously. Many studies showed that prophylactic chemotherapy for high risk hydatidiform moles could significantly decrease the incidence of malignancy. Thus, it is essential to discover a breakthrough to determine patients with high risk malignancy so that prophylactic chemotherapy can be started as soon as possible. Objectives: Development of a scoring system of risk factors as a predictor of hydatidiform mole malignant transformation. Materials and Methods: This research is a case control study with hydatidiform mole and choriocarcinoma patients as subjects. Multiple logistic regression was used to analyze the data. Odds ratios (OR), attributable at risk (AR : OR-1) and risk index ($ARx{\beta}$) were calculated for develoipment of a scoring system of malignancy risk. The optimal cut-off point was determined using receiver operating characteristic (ROC) curve. Results: This study analyzed 34 choriocarcinoma cases and 68 benign hydatidiform mole cases. Four factors significantly increased the risk of malignancy, namely age ${\geq}35$ years old (OR:4.41, 95%CI:1.07-16.09, risk index 5); gestational age ${\geq}$ 12weeks (OR:11.7, 95%CI:1.8-72.4, risk index 26); uterine size greater than the gestational age (OR:10.2, 95%CI:2.8-36.6, risk index 21); and histopathological grade II-III (OR:3.4, 95%CI:1.1-10.6, risk index 3). The lowest and the highest scores for the risk factors were zero and 55, respectively. The best cut-off point to decide high risk malignancy patients was ${\geq}31$. Conclusions: Malignant transformation of hydatidiform moles can be predicted using the risk scoring by analyzing the above four parameters. Score ${\geq}31$ implies high risk patients so that prophylactic chemotherapy can be promptly administered for prevention.

키워드

참고문헌

  1. Abdullah NM, Prabowo RP (1985). Hasil pengobatan neoplasma tropoblas ganas di RS. Dr. Soetomo Surabaya (1981-1983). Neoplasma tropoblas gestational, epidemiologi, diagnosis, pengobatan, pencegahan, Prognosis: 42-5.
  2. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C (2003). Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol, 4, 670-8. https://doi.org/10.1016/S1470-2045(03)01245-2
  3. Andrijono A, Muhilal M (2010). Prevention of post-mole malignant trophoblastic disease with vitamin A. Asian Pac J Cancer Prev, 11, 567-70
  4. Audu BM, Takai IU, Chama CM, Bukar M, KyariI O (2009). Hydatidiform mole as seen in a university teaching hospital: A 10-year review. J Obstet Gynaecol, 29, 322-5. https://doi.org/10.1080/01443610902807345
  5. Aziz MF, Kompono N, Samil RS (1995). Neoplasma trofoblas, faktor risiko tinggi dan prognosis. Neoplasma Trofoblas Gestational, 35-54.
  6. Barnas B, Aziz MF (1982). Hubungan klasifikasi histologik mola hidatidosa dengan penyakit trofoblas ganas. J Obstet Gynecol, 8, 168-72.
  7. Berkowitz RS, Goldstein DP (2007). Gestational tropoblastic disease. Berek Novaks Gynecology, 14, 2376-405.
  8. Bernirschke K, Burton GJ, Baergen RN (2012). Pathology of the Human Placenta. 6th Ed, Springer-Verlag Co, 687-723.
  9. Cunningham FG, Leveno KL, Bloom SL, et al (2010). Gestational Trophoblastid Disease. in Williams Obstetrics, 23th Ed. Mc Graw Hill Co, 257-65.
  10. Guzel AI, Kokanali MK, Erkilinc S, et al (2014). Predictive role of the neutrophil lymphocyte ratio for invasion with gestational trophoblastic disease. Asian Pac J Cancer Prev, 15, 4203-6. https://doi.org/10.7314/APJCP.2014.15.10.4203
  11. Hertig AT, Mansell H (1956) Hydatidiform Mole and Choriocarcinoma. in: Atlas of Tumor Pathoogy. Armed Forces of Pathology. Washington, DC
  12. Kampono N, Aziz MF, Sjamsudin S, Barnas B (1995). Pengobatan profilaksis pada mola hidatidosa dengan Actinomycin D. neoplasma trofoblas gestational. 62-7.
  13. Khanum F, Shamser S (2010). Gestational trophoblastic disease: experience at a tertiary care hospital of peshawar. JPMI, 94, 127-32.
  14. Khasimura Y, Khasimura M, Sugimori H, et al (1986). Prophylactic chemotherapy for hydatiform mole, five to 15 years follow-up. Cancer, 58, 624-9. https://doi.org/10.1002/1097-0142(19860801)58:3<624::AID-CNCR2820580305>3.0.CO;2-6
  15. Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY (1986). Effect of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol, 67, 690-4 https://doi.org/10.1097/00006250-198605000-00017
  16. Kurman R (1995). Gestational tropoblastic disease. 4th Ed, Arcata Graphics, 1067-86.
  17. Lurain J (1987). Gestational trophoblastic disease. Clinical manual of gynecology. 2nd ed. Beckman Ling (Edit.). Mac Graw Hill Inc. 543-56.
  18. Ngan HYS, Kohorn EI, Cole LA, et al (2012). Trophoblastic disease. Inter J Gynecol Obstet, 119, 130-6 https://doi.org/10.1016/j.ijgo.2012.05.019
  19. Ozalp SS, Telli E, Oge T, et al (2014). Multicenter analysis of gestational trophoblastic neoplasia in Turkey. Asian Pac J Cancer Prev, 15, 3625-8. https://doi.org/10.7314/APJCP.2014.15.8.3625
  20. Salehi S, Eloranta S, Johansson ALV, Bergstrom M, Lambe M (2011). Reporting and incidence trends of hydatidiform mole in Sweden 1973-2004. Acta Oncologica, 50, 367-72. https://doi.org/10.3109/0284186X.2010.512922
  21. Samadan-Cagayan MSF (2008). Efficacy of methotrexate as primary single agent therapy for non metastatic gestational trophoblastic neoplasia at the university of the Philippine-Philippine general hospital (UP+PGH). Cancer Therapy, 6, 611-6.
  22. Uberti EMH, Fajardo MDC, da Cunha AVG, et al (2009). Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatiform mole: a simple, effective, secure and low cost approach without adverse effects on compliance to general follow-up or subsequent treatment. Gynecol Oncol, 114, 299-305 https://doi.org/10.1016/j.ygyno.2009.04.006
  23. Wardhani H, Faisal Y, Nuria SM, Saleh AZ, Pohan HS (1991). Karakteristik kasus mola hidatidosa di RSU Palembang selama 2 tahun (1989-1990). POGI J, 67-72.

피인용 문헌

  1. Predictive value of some hematological parameters for non-invasive and invasive mole pregnancies vol.31, pp.3, 2018, https://doi.org/10.1080/14767058.2017.1281906